Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase II trial of Imbruvica showed that more than 30 percent of treated relapsed/refractory mantle cell lymphoma patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Forty-seven percent of the 111 patients treated were still living at the 27-month median follow-up.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

 For nearly 30 years, the American Cancer Society’s prostate cancer screening guidelines have advised men to discuss prostate-specific antigen, or PSA, testing with a clinician and weigh potential benefits and harms, rather than treat screening as an unquestioned routine. This “informed decision-making” recommendation was consistent with guidelines from all major professional organizations in the United States, Canada, and Europe. 
For patients with an HPV-related form of throat cancer, treatment is often highly effective, with cure rates as high as 90%, depending on the disease stage. Now, researchers are investigating whether some patients can safely avoid additional treatment while maintaining excellent cancer outcomes.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login